Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

November 20, 2018 |

1 min read

Array BioPharma Inc. today announced that its Chief Executive Officer, Ron Squarer, will speak at the 30th Annual Piper Jaffray Healthcare Conference in New York.

BOULDER, Colo., Nov. 20, 2018 /PRNewswire/ -- Array BioPharma, Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 30^th Annual Piper Jaffray Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Event:	30^th Annual Piper Jaffray Healthcare Conference
Presenter:	Ron Squarer, Chief Executive Officer, Array BioPharma
Date:	Tuesday, November 27, 2018
Time:	9:00 a.m. Eastern Time
Webcast:	https://event.webcasts.com/starthere.jsp?ei=1220218&tp_key=8e5fb74efb

About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI^® (encorafenib) capsules in combination with MEKTOVI^®(binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation. Array’s lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array’s pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Ganovo^® (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.